Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel + sunitinib with FDG-PET response assessment in progressive pancreatic neuroendocrine tumor
2012-003936-21Phase 2Terminated
- Sponsor
- Hôpital de Jolimont
- Start
- Sep 2013
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide and sunitinib in islet cell tumor, sponsored by Hôpital de Jolimont. Primary endpoints: Baseline 18F-FDG status clustering and Correlation of early 18F-FDG PET changes with time to tumor progression. Started Sep 2013; status: terminated.
02
Drugs
lanreotidesunitinib
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2012-003936-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003936-21.